BETHESDA, Md.--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today that it presented promising early data from a Phase Ib study of indibulin, the Company’s novel, orally administered, synthetic tubulin targeted agent, at the 6th International Symposium on Targeted Anticancer Therapies held in Bethesda, Maryland, March 20 to 22.
